- inhibitors.
Temsirolimus' high
level of
specificity for mTOR
likely contributes to the
tolerability of
temsirolimus. However,
temsirolimus increases mortality...
-
everolimus (RAD001), and
temsirolimus (CCI-779), are the
newly developed rapamycin analogs. The
rapamycin analog temsirolimus (CCI-779) is also a noncytotoxic...
- clear-cell carcinoma;
cytokine therapy (IL-2, interferon),
kinase inhibitors (
temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic
therapies (bevacizumab)...
- the use of
alternate dosing regimens or
analogs such as
everolimus or
temsirolimus. Lung
toxicity is a
serious complication ****ociated with
sirolimus therapy...
-
There is a
phase I/II
study at the Mayo
Clinic of
sorafenib and CCI-779 (
temsirolimus) for
recurrent glioblastoma. A
study performed in 2008
showed that sorafenib...
- two
primary mTOR
inhibitors used in the
treatment of
human cancers,
temsirolimus and everolimus. mTOR
inhibitors have
found use in the
treatment of a...
-
Phase 2b
study (TARGET trial) in non-small-cell lung
carcinoma (NSCLC).
Temsirolimus (Torisel)
Everolimus (Afinitor)
Vemurafenib (Zelboraf)
Trametinib (Mekinist)...
-
treatment of Alzheimer's
disease and bevacizumab, sorafenib,
sunitinib and
temsirolimus for
renal cell carcinoma. All
these are
drugs with a high cost per treatment...
- IL-1
receptor antagonists Anakinra mTOR
Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus...
- Cancer" at ClinicalTrials.gov
Clinical trial number NCT01016015 for "
Temsirolimus and
Cixutumumab in
Treating Patients With
Locally Advanced, Metastatic...
